UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 OF THE
SECURITIES EXCHANGE ACT OF 1934
For the month March 2012
(Commission File No. 001-35193)
Grifols, S.A.
(Translation of registrants name into English)
Avinguda de la Generalitat, 152-158
Parc de Negocis Can Sant Joan
Sant Cugat del Valles 08174
Barcelona, Spain
(Address of registrants principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F x Form 40-F ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101 (b) (1):
Yes ¨ No x
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101 (b) (7):
Yes ¨ No x
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes ¨ No x
If Yes is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82- . .
Grifols, S.A.
TABLE OF CONTENTS
Item |
Sequential Page Number | |
2 |
Grifols, S.A. announces that it has acquired 51% of the share capital of Araclon Biotech, S.L.
Araclon Biotech is a company whose corporate activity is the research and development of therapies and methods for the diagnosis of degenerative illnesses, presently concentrating on Alzheimers disease.
Presently, the main activity of Araclon is to validate and market a blood diagnostic kit of Alzheimers disease for detecting beta amyloid proteins 40 and 42 (patented) and the development of an efficient immunotherapy treatment of Alzheimers disease.
Araclon Biotech was founded by Dr Manuel Sarasa, who is the companys Scientific Director.
Dr Manuel Sarasa is a neurobiologist and embryologist. He is a Lecturer of Anatomy and Comparative Pathological Anatomy for the University of Zaragoza, and has more than 25 years of experience in basic investigation and more than 18 years of research on subjects related to Alzheimers disease.
With this acquisition, Grifols reinforces its commitment to the research and development of therapies to fight Alzheimers disease.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereto duly authorized.
Grifols, S.A. | ||
By: | /s/ David I. Bell | |
Name: | David I. Bell | |
Title: | Authorized Signatory |
Date: March 15, 2012
3